Transurethral treatment for erectile dysfunction
MUSE - Medical Urethral System for Erection - marketed in Italy by Meda, is the first and only transurethral treatment currently on the market, approved by the FDA in 1996 and by MCA in the United Kingdom in 1997.
Muse is a trans urethral device that consists of an applicator and a medicated system containing alprostadil (PGE1) that is administered as needed by inserting the stick into the urethra with subsequent pressure on the top of the applicator for drug release.
The method of administration makes Muse an authentic novelty in the field of treatments against impotence: effective in organic erectile dysfunction of any nature, regardless of the age of the patient, it acts quickly over 10 minutes and ensures an erection of 30-60 minutes duration. The advantages are obvious compared to the apricodil administered by intracavernous injection: it is less invasive, has fewer side effects and significantly increases compliance. Less pain, less burning, greater patient satisfaction. From the pharmacokinetic point of view, Muse is rapidly metabolized, both locally and in the pulmonary capillaries: the metabolites are excreted in the urine (90% within 24 hours) and in the faeces and there is no evidence that alprostadil or its metabolites accumulate in the tissues.
Real alternative in the treatment of erectile dysfunctions, Muse is destined to change the habits of the users of intracavernous alprostadil and beyond.
Users of the blue pill may also be interested in trying a system that does not have the known side effects of oral treatments and offers many advantages. In fact, alprostadil, unlike oral medicines that treat erectile dysfunction, directly causes the relaxation of smooth muscles even in the absence of sexual stimulation, while oral drugs are effective only in the presence of central or reflex sexual stimulation.
